Table 1.
Mainly clinical trial and target therapies
| Study | Design | Median PFS (mo) | Median OS (mo) | Toxicity (grade 3/4) | Genetic analyses | Response rate |
| PACCE trial[18] | PMAB + Bev/Ox-CT | 10 | 19.4 | Skin rash, diarrhea, infections and pulmonary embolism | KRAS status was determined in 82% tumor samples. Mutations were found in 40% | 46% |
| + | ||||||
| PMAB + Bev/Iri-CT | ||||||
| Bev/Ox-CT | 11.4 | 24.5 | 48% | |||
| + | ||||||
| Bev/Iri-CT | ||||||
| Peeters et al[22] | Panitumumab-FOLFIRI (in the WT KRAS subpopulation) | 5.9 | 14.51 | Toxicities associated with anti-EGFR therapy | KRAS status was available for 91% of patients: 597 (55%) with wild-type KRAS tumors, and 486 (45%) with mutant KRAS tumors | Improved to 35% vs 10% with the addition of panitumumab |
| FOLFIRI (in the WT KRAS subpopulation) | 3.9 | 12.51 | ||||
| PRIME study[28] | Wild-type KRAS stratum Panitumumab + | 9.6 | 23.91 | Toxicities associated with anti-EGFR therapy | KRAS results were available for 1100 ( 93%)patients | 55% |
| FOLFOX (4) | ||||||
| FOLFOX(4) | 8.0 | 19.71 | ||||
| Mutant KRAS stratum | 48% | |||||
| Panitumumab + | 7.3 | 15.51 | 40% | |||
| FOLFOX (4) | ||||||
| FOLFOX (4) | 8.8 | 19.31 | 40% | |||
| COIN trial[29] | Ox and 5FU (arm A) in KRAS wild-type tumours | 8.61 | 17.91 | NA | 565 (43%) had KRAS mutations | 57% |
| Ox and 5FU plus cetuximab (arm B) in KRAS wild-type tumours | 8.61 | 17.01 | Skin rash and gastrointestinal toxic effects | 64% | ||
| NORDIC-VII[20] | Standard Nordic FLOX (arm A) | 7.91 | 20.41 | The regimens were well tolerated | KRAS and BRAF mutation analyses were obtained in 498 (88%) and 457 patients (81%) respectively | 41% |
| Cetuximab and FLOX (arm B) | 8.31 | 19.71 | 49% | |||
| Cetuximab combined with intermittent FLOX (arm C) | 7.31 | 20.31 | 47% |
1
Without statistical significance. PFS: Progression-free survival; OS: Overall survival; PMAB: Panitumumab; Bev: Bevacizumab; Ox:CT: Oxaliplatin:based chemotherapy; Iri-CT: Irinotecan-based chemotherapy; 5FU: 5-fluorouracil; FOLFOX/FLOX: Fluorouracil, leucovorin and oxaliplatin; FOLFIRI: Fluorouracil, leucovorin and irinotecan; NA: Not applicable.